News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
This opens up a huge market for the company’s Magnezis implants in India
The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries
It recommends using the vaccine to prevent the spread of the disease
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
